WhichPeps

SLU-PP-332

Synthetic small-molecule estrogen-related receptor agonist

Exercise-mimeticmetabolism and obesity…
Generic peptide vial illustrationSLU-PP-332
Evidence levelPreclinical only
Human evidenceNone established
Regulatory statusNo FDA/EMA approval identified

What you need to know in 20 seconds

What is it?Synthetic small-molecule estrogen-related receptor agonist
Research focusExercise-mimetic, metabolism and obesity research
Human evidenceNo therapeutic human administration evidence identified. A 2026 human-liver S9 study addresses metabolism/detection, not clinical exposure.
Regulatory statusNo FDA/EMA-approved medicine identified.
Main limitationsHuman exercise enhancement, weight loss, dose, pharmacokinetics, interactions or long-term safety.
SafetyHuman PK, toxicity, carcinogenicity/reproductive safety and therapeutic window are unknown.
i
No therapeutic human administration evidence identified. A 2026 human-liver S9 study addresses metabolism/detection, not clinical exposure.

What the evidence actually supports

  • ✓Present as preclinical exercise-mimetic research only.
  • ✓High-interest trend page, but firmly preclinical.

What is not established / key limitations

  • ×No human endurance, dose, PK or safety data.
  • ×No established human weight-loss effect or safe therapeutic window.

Selected study & evidence records

SLU-PP-332 exercise-mimetic study

2023 · Preclinical mechanistic/animal study

SLU-PP-332 increased oxidative muscle features and enhanced exercise endurance in mice through ERR-dependent signalling.

Study detail → Primary source ↗

SLU-PP-332 metabolic syndrome study

2023 · Preclinical animal study

The study reported increased energy expenditure/fat oxidation and improved metabolic phenotypes in mice.

Study detail → Primary source ↗

In-vitro human liver metabolism study for SLU-PP-332

2026 · In-vitro human-derived metabolism / anti-doping study

Human-derived liver metabolism work identified metabolites relevant to detection, but did not administer the compound to people.

Study detail → Primary source ↗

Safety and unknowns

Human PK, toxicity, carcinogenicity/reproductive safety and therapeutic window are unknown.

Human pharmacokinetics, therapeutic window, organ toxicity, cardiovascular risk and long-term safety are unknown.

Technical details

Mechanism / biologyPan-ERR agonist that activates transcriptional programmes associated with oxidative metabolism/exercise adaptation in experimental models.
Route / formulation boundaryThis is a small molecule, not a peptide. Oral commercial capsules are not validated by preclinical papers.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusDosing research conclusion recorded. No human dosing regimen identified; current literature remains preclinical, medicinal-chemistry and analytical.
Identifiers & alternate namesSLU PP 332 · SLUPP332 · Slu-PP 332

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.